Bio-Rad Laboratories, Inc.

NYSE:BIO Stock Report

Market Cap: US$9.2b

Bio-Rad Laboratories Management

Management criteria checks 4/4

Bio-Rad Laboratories' CEO is Norman Schwartz, appointed in Jan 2003, has a tenure of 21.92 years. total yearly compensation is $7.46M, comprised of 13.9% salary and 86.1% bonuses, including company stock and options. directly owns 4.34% of the company’s shares, worth $401.28M. The average tenure of the management team and the board of directors is 3.5 years and 7.7 years respectively.

Key information

Norman Schwartz

Chief executive officer

US$7.5m

Total compensation

CEO salary percentage13.9%
CEO tenure21.9yrs
CEO ownership4.3%
Management average tenure3.5yrs
Board average tenure7.7yrs

Recent management updates

Recent updates

Is Bio-Rad Laboratories (NYSE:BIO) Using Too Much Debt?

Dec 16
Is Bio-Rad Laboratories (NYSE:BIO) Using Too Much Debt?

Why Bio-Rad Laboratories Is Overvalued: A Fundamental And DCF Analysis

Nov 25

Is Bio-Rad Laboratories, Inc. (NYSE:BIO) Potentially Undervalued?

Nov 25
Is Bio-Rad Laboratories, Inc. (NYSE:BIO) Potentially Undervalued?

A Look At The Intrinsic Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Nov 04
A Look At The Intrinsic Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Bio-Rad Laboratories: Overvalued Given Current Growth Prospects

Sep 23

We Think Bio-Rad Laboratories (NYSE:BIO) Can Stay On Top Of Its Debt

Sep 08
We Think Bio-Rad Laboratories (NYSE:BIO) Can Stay On Top Of Its Debt

Bio-Rad Laboratories, Inc.'s (NYSE:BIO) Shares May Have Run Too Fast Too Soon

Jul 18
Bio-Rad Laboratories, Inc.'s (NYSE:BIO) Shares May Have Run Too Fast Too Soon

Bio-Rad: Economics Unsupportive With Capital Valued 70 Cents On The Dollar

Jul 14

Bio-Rad Laboratories (NYSE:BIO) Has A Pretty Healthy Balance Sheet

Apr 18
Bio-Rad Laboratories (NYSE:BIO) Has A Pretty Healthy Balance Sheet

Bio-Rad: A Lackluster Picks-And-Shovels Life Science Company With A Key Investment Kicker

Apr 14

At US$325, Is Bio-Rad Laboratories, Inc. (NYSE:BIO) Worth Looking At Closely?

Feb 07
At US$325, Is Bio-Rad Laboratories, Inc. (NYSE:BIO) Worth Looking At Closely?

Bio-Rad: Business Returns Aren't Economically Valuable, Sartorius Now A Hindrance

Oct 25

Bio-Rad: A Cash Flow Returns On Investments Analysis

Aug 10

Bio-Rad Labs reports Q4 2022 results

Feb 16

Bio-Rad: How Efficient Is Its Capital Management? A Deep Look, With Technicals

Jan 04

Bio-Rad Labs Non-GAAP EPS of $2.60 misses by $0.17, revenue of $680.8M misses by $1.9M

Oct 27

Will Bio-Rad And Qiagen Merge? I Can't See Any Logic To This Deal

Oct 12

Bio-Rad Laboratories hits 52-week low; down 40% YTD

Sep 19

Bio-Rad Labs Non-GAAP EPS of $3.38 beats by $0.67, revenue of $691.1M beats by $26.5M

Jul 28

CEO Compensation Analysis

How has Norman Schwartz's remuneration changed compared to Bio-Rad Laboratories's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$779m

Jun 30 2024n/an/a

-US$1b

Mar 31 2024n/an/a

-US$322m

Dec 31 2023US$7mUS$1m

-US$637m

Sep 30 2023n/an/a

-US$159m

Jun 30 2023n/an/a

-US$428m

Mar 31 2023n/an/a

-US$191m

Dec 31 2022US$8mUS$1m

-US$4b

Sep 30 2022n/an/a

-US$6b

Jun 30 2022n/an/a

-US$2b

Mar 31 2022n/an/a

-US$91m

Dec 31 2021US$9mUS$988k

US$4b

Sep 30 2021n/an/a

US$7b

Jun 30 2021n/an/a

US$4b

Mar 31 2021n/an/a

US$4b

Dec 31 2020US$8mUS$987k

US$4b

Sep 30 2020n/an/a

US$4b

Jun 30 2020n/an/a

US$2b

Mar 31 2020n/an/a

US$2b

Dec 31 2019US$7mUS$950k

US$2b

Sep 30 2019n/an/a

US$377m

Jun 30 2019n/an/a

US$905m

Mar 31 2019n/an/a

US$574m

Dec 31 2018US$8mUS$942k

US$366m

Sep 30 2018n/an/a

US$1b

Jun 30 2018n/an/a

US$1b

Mar 31 2018n/an/a

US$767m

Dec 31 2017US$5mUS$922k

US$122m

Compensation vs Market: Norman's total compensation ($USD7.46M) is about average for companies of similar size in the US market ($USD7.98M).

Compensation vs Earnings: Norman's compensation has been consistent with company performance over the past year.

CEO

Norman Schwartz (74 yo)

21.9yrs

Tenure

US$7,463,878

Compensation

Mr. Norman D. Schwartz was Principal Financial Officer of Bio-Rad Laboratories, Inc. since February 9, 2024 until April 15, 2024 and served as its Interim CFO until February 9, 2024. He serves as an Indepe...

Leadership Team

NamePositionTenureCompensationOwnership
Norman Schwartz
Chairman & CEO21.9yrsUS$7.46m4.34%
$ 401.3m
Jonathan DiVincenzo
President & COOless than a yearno datano data
Roop Lakkaraju
Executive VP & CFOless than a yearno datano data
Tania DeVilliers
Senior Director3.5yrsno data0.00020%
$ 18.5k
Yong Chung
Vice President of Investor Relationsno datano datano data
Matthew Werner
Senior Vice President and Chief Compliance & Privacy Officerno datano datano data
Courtney Enloe
Executive VPless than a yearno datano data
Colleen Corey
Executive Vice President of Global Human Resources10.7yrsno data0.066%
$ 6.1m
Michael Crowley
Executive Vice President of Global Commercial Operations10yrsUS$2.68m0.029%
$ 2.7m
Lee Boyd
Senior Vice President of Global Commercial Operations - Asia Pacificno datano datano data
James Barry
Executive VP & President of Life Science Groupno datano data0.00053%
$ 49.0k
Kurt DeLanghe
Senior Vice President of Global Commercial Operations of Europeno datano datano data

3.5yrs

Average Tenure

60yo

Average Age

Experienced Management: BIO's management team is considered experienced (3.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Norman Schwartz
Chairman & CEO29.9yrsUS$7.46m4.34%
$ 401.3m
Gregory Hinckley
Lead Independent Director7.7yrsUS$199.25k0.0018%
$ 165.6k
Alice Schwartz
Director Emeritus2.7yrsUS$40.18k11.46%
$ 1.1b
Jeffrey Edwards
Independent Director7.7yrsUS$190.00kno data
Arnold Pinkston
Independent Director7.7yrsUS$178.75kno data
Melinda Pei
Independent Director7.7yrsUS$195.00kno data
Allison Schwartz
Director2.7yrsno data0.019%
$ 1.7m

7.7yrs

Average Tenure

66yo

Average Age

Experienced Board: BIO's board of directors are considered experienced (7.7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/27 06:08
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Bio-Rad Laboratories, Inc. is covered by 27 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ishan MajumdarBaptista Research
Jon WoodBofA Global Research
Sel HardyCFRA Equity Research